Belumosudil for chronic graft-versus-host disease

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Chronic graft-versus-host disease (cGvHD) is a serious complication of allogeneic hematopoietic cell transplantation, causing significant morbidity and mortality.
• The Rho-associated coiled-coil-containing protein kinase (ROCK) pathway is implicated in cGvHD's inflammatory and fibrotic processes.
• Existing ROCK inhibitors often lack selectivity, leading to dose-limiting toxicities.

Purpose of the Study:

• To review preclinical and clinical evidence for belumosudil mesylate, a selective ROCK2 inhibitor.
• To highlight the development and FDA approval of belumosudil for cGvHD treatment.

Main Methods:

• Review of preclinical studies investigating ROCK2 inhibition in cGvHD models.
• Analysis of clinical trial data assessing the safety and efficacy of belumosudil mesylate.
• Examination of regulatory submissions leading to FDA approval.

Main Results:

• Belumosudil mesylate demonstrated safety and efficacy in treating cGvHD.
• The drug is approved for adult and pediatric patients 12 years and older with cGvHD post-failure of at least two prior systemic therapies.
• Belumosudil is the first and only FDA-approved therapy targeting ROCK2 for cGvHD.

Conclusions:

• Belumosudil mesylate represents a significant advancement in cGvHD management.
• Targeting ROCK2 with selective inhibitors offers a promising therapeutic strategy for cGvHD.
• The approval of belumosudil provides a much-needed option for patients with refractory cGvHD.